Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART19 in pediatric relapsed/refractory B-ALL
NCT02808442Phase 1Completed
- Sponsor
- Servier
- Start
- Jun 2016
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Servier. Primary endpoint: Incidence and Severity of Adverse Events at Month 12. Started Jun 2016; status: completed.
02
Drugs
UCART19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02808442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808442.